New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins

[1]  R. Camire,et al.  Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity. , 2015, Blood.

[2]  G. Pierce,et al.  Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion. , 2015, Thrombosis research.

[3]  S. Milstein,et al.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia , 2015, Nature Medicine.

[4]  S. Lethagen,et al.  Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial , 2015, Journal of thrombosis and haemostasis : JTH.

[5]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[6]  Dulce M Santos,et al.  Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein. , 2015, Molecular immunology.

[7]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[8]  G. Spotts,et al.  Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis , 2014 .

[9]  T. Nichols,et al.  Unexpected Role of PACE/Furin Cleavage Site in FVIII Biology: Implications for Hemophilia a Therapy , 2014 .

[10]  R. Camire,et al.  A Zymogen-like Factor Xa Improves Hemostasis in a Murine Bleeding Model , 2014 .

[11]  U. Reineke,et al.  A TFPI Inhibitory Half Life Extended Fusion Peptide Proves Efficacy in FVIII Knock out Mice and Marmoset Monkeys , 2014 .

[12]  J. Griffin,et al.  Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors , 2014 .

[13]  Tetsuji Sato,et al.  Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII Inhibitors: First-in-Patient Phase 1 Study , 2014 .

[14]  E. Santagostino,et al.  Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP) , 2014 .

[15]  A. Strahs,et al.  A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B , 2014 .

[16]  L. Boggio,et al.  Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study , 2014 .

[17]  K. Nogami,et al.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. , 2014, Blood.

[18]  J. Dumont,et al.  Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels , 2014, Journal of thrombosis and haemostasis : JTH.

[19]  J. Rosing,et al.  Inhibition of tissue factor:factor VIIa–catalyzed factor IX and factor X activation by TFPI and TFPI constructs , 2014, Journal of thrombosis and haemostasis : JTH.

[20]  J. Griffin,et al.  An Engineered Factor Va Prevents Bleeding Induced by Anticoagulant wt Activated Protein C , 2014, PloS one.

[21]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[22]  J. Griffin,et al.  Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant , 2014, Journal of thrombosis and haemostasis : JTH.

[23]  T. Weimer,et al.  Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) , 2014, Journal of thrombosis and haemostasis : JTH.

[24]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[25]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[26]  H. Ehrlich,et al.  Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)* , 2013, The Journal of Biological Chemistry.

[27]  C. Joch,et al.  Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers , 2013, Journal of thrombosis and haemostasis : JTH.

[28]  M. Ozelo,et al.  Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  T. Weimer,et al.  Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin , 2013, Thrombosis and Haemostasis.

[30]  P. Giangrande,et al.  40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors , 2013, Journal of thrombosis and haemostasis : JTH.

[31]  J. Oldenburg,et al.  Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. , 2013, Blood.

[32]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[33]  A. Lubetsky,et al.  Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. , 2013, Thrombosis research.

[34]  P. Reitsma,et al.  New fundamentals in hemostasis. , 2013, Physiological reviews.

[35]  Tsukasa Suzuki,et al.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.

[36]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[37]  A. Gruhler,et al.  Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. , 2012, Blood.

[38]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[39]  A. Bitonti,et al.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. , 2012, Blood.

[40]  A. Neff,et al.  Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[41]  R. Kontermann.  Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[42]  P. Margaritis,et al.  A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia , 2011, Nature Biotechnology.

[43]  R. Camire,et al.  Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. , 2008, Blood.

[44]  A. Neff,et al.  Survey of Current Prophylaxis Practices and Bleeding Characteristics of Children with Severe Hemophilia A In U.S. Hemophilia Treatment Centers. , 2010 .

[45]  L. Valentino.  Controversies regarding the prophylactic management of adults with severe haemophilia A , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[46]  T. Weimer,et al.  Genetic fusion to albumin improves the pharmacokinetic properties of factor IX , 2009, Thrombosis and Haemostasis.

[47]  L. Valentino,et al.  Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[48]  M. Trucco,et al.  Risk factors for inhibitor formation in haemophilia: a prevalent case–control study , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[50]  J. Stockman.  Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[51]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[52]  S. Kaveri,et al.  Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. , 2008, Blood.

[53]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[54]  C. Hay.  Prophylaxis in adults with haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  J. G. van der Bom,et al.  Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. , 2007, Blood.

[56]  J. Stadler,et al.  PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies , 2007, Drug Metabolism and Disposition.

[57]  F. Lafeber,et al.  Pathogenesis of haemophilic arthropathy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[58]  M. Radmacher,et al.  Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[59]  A. Azadi,et al.  Pharmacokinetic Consequences of Pegylation , 2006, Drug delivery.

[60]  A. Bitonti,et al.  Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. , 2006, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[61]  D. Scott,et al.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. , 2005, Blood.

[62]  M. A. Rothschild,et al.  Serum albumin , 2005, The American Journal of Digestive Diseases.

[63]  L. Valentino.  Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[64]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[65]  D. Brettler,et al.  Home‐based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[66]  J. Goudemand.  Pharmaco‐economic aspects of inhibitor treatment , 1998, European journal of haematology. Supplementum.

[67]  Samuel Zalipsky,et al.  Poly(ethylene glycol): Chemistry and Biological Applications , 1997 .

[68]  M. Hershfield.  Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA) , 1997 .

[69]  Y. Borel.  Haptens Bound to Self IgG Induce Immunologic Tolerance, While When Coupled to Syngeneic Spleen Cells They Induce Immune Suppression , 1980, Immunological reviews.